Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole dosing for ovulation induction in polycystic ovary syndrome
IRCT20240109060656N4Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of letrozole in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Ovulation rate. Started Jul 2025; status: completed.
02
Drugs
letrozole
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20240109060656N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240109060656N4.